A Novel Approach Based on Gut Microbiota Analysis and Network Pharmacology to Explain the Mechanisms of Action of Cichorium intybus L. Formula in the Improvement of Hyperuricemic Nephropathy in Rats
Mukaram Amatjan,Na Li,Pengke He,Boheng Zhang,Xianyan Mai,Qianle Jiang,Haochen Xie,Xiaoni Shao
DOI: https://doi.org/10.2147/DDDT.S389811
2023-01-20
Abstract:Mukaram Amatjan, 1 Na Li, 1 Pengke He, 1 Boheng Zhang, 1 Xianyan Mai, 1 Qianle Jiang, 1 Haochen Xie, 2 Xiaoni Shao 1 1 Immunotherapy Laboratory, College of Pharmacology, Southwest Minzu University, Chengdu, 610225, People's Republic of China; 2 Qinghai Tibet Plateau Research Institute, Southwest Minzu University, Chengdu, 610225, People's Republic of China Correspondence: Xiaoni Shao, Immunotherapy Laboratory, College of Pharmacology, Southwest Minzu University, &num168 Dajian Street, Shuangliu District, Chengdu, 610225, People's Republic of China, Tel +86-28-85738423, Email Background: Cichorium intybus L. formula (CILF) is a traditional Chinese medicine (TCM) widely used in the treatment of gout and hyperuricemic nephropathy (HN). The aim of this research was to investigate the potential protective effect of CILF against HN and elucidated the underlying mechanism. Methods: CILF water extract was administered to an HN rat model established by adenine combined with ethambutol. The levels of uric acid (UA), serum urea nitrogen (UREA), and creatinine (CREA) were detected. Changes in the pathology and histology of the kidney were observed by hematoxylin-eosin staining. The 16S rRNA of the gut microbiota was sequenced. The binding ability of the main ingredients of CILF to key targets was analyzed by network pharmacology and molecular docking. The expression levels of the related mRNAs and proteins in the kidney were evaluated by RT-qPCR and immunohistochemistry analysis. Results: CILF administration significantly alleviated increases in UA, UREA, and CREA, structural damage, and kidney dysfunction. Gut microbiota analysis was applied to explore the pharmacological mechanism of the effects of CILF on bacterial diversity and microbiota structure in HN. CILF decreased the abundance of Bacteroides . In addition, it increased the abundance of Lactobacillaceae, Erysipelotrichaceae, Lachnospiraceae, Ruminococcaceae , and Bifidobacterium . Based on network pharmacology and molecular docking analysis, CILF profoundly influenced the IL17, TNF and AGE-RAGE signaling pathway. Additionally, CILF inhibited the expression of STAT3, VEGFA and SIRT1 to improve the symptoms of nephropathy. Our research suggested that CILF protects against kidney dysfunction in rats with HN induced by adenine combined with ethambutol. Conclusion: Our findings on the anti-HN effects of CILF and its mechanism of action, from the viewpoint of systems biology, and elaborated that CILF can alter the diversity and community structure of the gut microbiota in HN, providing new approaches for the prevention and treatment of HN. Keywords: Cichorium intybus L. formula, hyperuricemic nephropathy, gut microbiota, network pharmacology, molecular docking Hyperuricemia can lead to chronic kidney disease (CKD) and end-stage renal disease. The main pathological basis is that luminescent crystals are deposited in the kidney collecting tubules, resulting in acute renal injury and renal disease. 1 Due to the complex pathogenesis of hyperuricemic nephropathy (HN), the lack of any effective clinical treatment will allow the disease to progress. Adenine increased serum UREA and CREA concentrations and excretion of UA in urine, produced proteinuria and induced kidney atrophy and fibrosis. 2 At the same time, ethambutol can inhibit the secretion of UA by the renal tubules, thereby inhibiting the excretion of UA by the kidneys and increasing serum UA, leading to kidney damage. 3 Previous reports have suggested that adenine in combination with ethambutol induces HN. 4,5 Renal damage caused by inducing chronic high levels of UA is sufficient to cause HN. Currently, the treatment of HN is mainly achieved by reducing UA levels and improving the symptoms of kidney disease. 6 There are a number of Western medicines available for the treatment of HN, such as febuxostat, allopurinol and benzbromarone. 7–9 Although they are very effective, they inevitably produce varying degrees of adverse effects, such as fatal hepatic failure and hypersensitivity syndrome. 10,11 Compared to Western medicines, traditional Chinese medicine (TCM) has the advantages of milder action and fewer adverse effects. 12 TCM is an unmet medical need in HN clinical research. According to TCM theory, defects in the spleen and kidney are the fundamental pathogenesis of HN, resulting in the failure of grain and water transportation and transformation, as well as the blockage of dampness and phlegm in meridian. 13 Therefore, clinical treatment focuses on dampness-heat, blood stasis and deficien -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal